Industry News

                            24 2020-08


                            Recently (July 14), Roche announced that its CD20xCD3 T cell combined with dual-characteristic cancer immunotherapy mosunetuzumab has received FDA Breakthrough Therapy Designation (BTD). Dr. Levi Garraway, Roches Chief Medical Officer and He...
                            24 2020-08


                            Last week, during the review process of GlaxoSmithKlines targeted BCMA-ADC (antibody-drug conjugate)---Belantamab mafodotin, FDA staff expressed concern about the ocular toxicity and side effects of the drug treatment, although Ge Lan Su Shi...
                            24 2020-08


                            On July 15, 2020, San Diego BioAtla, Inc. (BioAtla) is a global clinical stage biotechnology company dedicated to the development of conditional activated biological (CAB) antibody therapies. It announced the completion of the D round of fin...
                            • Contact information
                            • Sales:0512-85557988
                            • Personnel Department:0512-85557181
                            • Purchasing Department:0512-85557182
                            • Links

                            Follow WeChat public account

                            Copyright ? 2020 Jiangsu Greature Bio-Medicine Co., Ltd All Rights Reserved. 備案號: 蘇ICP備20037874號 技術支持:蘇州網站建設
                            share to:
                            一鍵撥號 一鍵導航